It is Transgene's second most advanced neoantigen immunotherapy programme after TG4050 for head and neck cancer, which is in ...

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to ...

Shares of French biotech Transgene (tumbled 13.5% to 1.01 euros by late morning after it announced that its randomized Phase ...

双sgRNA系统具有精确和高效编辑的特性，报告RNA富集的RNP系统具有transgene-free、编辑效率高、细胞毒性低、脱靶效应低的特性。因此，利用RE-DSRNP制备 ...

Transgene’s therapeutic cancer vaccine candidate has failed a mid-stage test in certain HPV-driven cancers, sending its ...

Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.

Transgene announced that its randomized Phase II study to evaluate TG4001 in combination with avelumab versus avelumab alone in ...

The posters are available on the Posters and Publications page of the Company’s website.

Transgene will present median 24-month follow up data from patients enrolled in the Phase I trial evaluating the individualized cancer vaccine TG4050 in the adjuvant treatment of head and neck cancer ...

On the second Monday of October, Americans will be celebrating Indigenous Peoples’ Day, also known as Columbus Day.

21点评：今年5月，恒瑞医药曾公告显示，该PD-1联用方案上市申请遭到FDA拒绝，原因是生产相关的问题。根据公告，FDA需要全面评估企业在生产场地检查缺陷的完整答复，并且由于部分国家的旅行限制，FDA在审查周期内无法完成该项目必需的生物学研究监测计划 ...

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at ...